1.
Competing risk bias was common in Kaplan–Meier risk estimates published in prominent medical journals
by van Walraven, Carl
Journal of clinical epidemiology, 2016, Vol.69, p.170-173.e8
2.
Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controll...
by Yusuf, S
The Lancet (British edition), 2008, Vol.372 (9644), p.1174-1183
3.
Competing risk bias in Kaplan–Meier risk estimates can be corrected
by van Walraven, Carl
Journal of clinical epidemiology, 2016, Vol.70, p.101-105
4.
Real-world time on treatment with immuno-oncology therapy in recurrent/metastatic head and neck squamous cell carcinoma
by Ramakrishnan, Karthik
Future oncology (London, England), 2021-05-01, Vol.17 (23), p.3037-3050
5.
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
by Rittmeyer, Achim, MD
The Lancet (British edition), 2016, Vol.389 (10066), p.255-265
6.
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
by Bruix, Jordi, Dr
The Lancet (British edition), 2016, Vol.389 (10064), p.56-66
7.
Chemotherapy and radiotherapy in nasopharyngeal carcinoma: an update of the MAC-NPC meta-analysis
by Blanchard, Pierre, MD
The lancet oncology, 2015, Vol.16 (6), p.645-655
8.
Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial
by Henao-Restrepo, Ana Maria, MD
The Lancet (British edition), 2015, Vol.386 (9996), p.857-866
9.
Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, plat...
by James, Nicholas D, Prof
The Lancet (British edition), 2015, Vol.387 (10024), p.1163-1177
10.
Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial
by Wu, Yi-Long
The lancet oncology, 2017-11, Vol.18 (11), p.1454-1466
11.
Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): a multicentre, randomised, phase 3 trial
by Leiter, Ulrike, Dr
The lancet oncology, 2016, Vol.17 (6), p.757-767
12.
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial
by Shapiro, Joel, Dr
The lancet oncology, 2015, Vol.16 (9), p.1090-1098
13.
Stereotactic radiosurgery for patients with multiple brain metastases (JLGK0901): a multi-institutional prospective observational study
by Yamamoto, Masaaki, Prof
The lancet oncology, 2014, Vol.15 (4), p.387-395
14.
A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma
by Huang, Alexander C
Nature medicine, 2019-03, Vol.25 (3), p.454-461
15.
Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01)
by Uesaka, Katsuhiko, MD
The Lancet (British edition), 2016, Vol.388 (10041), p.248-257
16.
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
by Balar, Arjun V, Dr
The Lancet (British edition), 2016, Vol.389 (10064), p.67-76
17.
Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase...
by Neoptolemos, John P, Prof
The Lancet (British edition), 2017, Vol.389 (10073), p.1011-1024
18.
Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, c...
by Le Tourneau, Christophe, Dr
The lancet oncology, 2015, Vol.16 (13), p.1324-1334
19.
Fusobacterium nucleatum in colorectal carcinoma tissue and patient prognosis
by Mima, Kosuke Kosuke
Gut, 2015-08-26, Vol.65 (12), p.1973-1980
20.
Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial
by Tawbi, Hussein A
The lancet oncology, 2017-11, Vol.18 (11), p.1493-1501
